Table 1.
Association between CD73 expression in CRLM and soluble CD73 serum level with clinicopathological factors.
| Variable | Patients N (%) | tCD73 (MFI) | SEM | P value | Patients N (%) | sCD73 (ng/mL) | SEM | P value |
|---|---|---|---|---|---|---|---|---|
| Age at hepatectomy | ||||||||
| ≤65 years | 111 (53.6) | 450.2 | 31.7 | 0.469 | 105 (54.4) | 2.97 | 0.23 | 0.651 |
| >65 years | 96 (46.4) | 405.6 | 24.6 | 88 (45.6) | 2.85 | 0.24 | ||
| Gender | ||||||||
| Male | 135 (65.2) | 401.4 | 21.7 | 0.093 | 126 (65.3) | 2.82 | 0.19 | 0.521 |
| Female | 72 (34.8) | 482.2 | 42.1 | 67 (34.7) | 3.09 | 0.30 | ||
| Timing of metastasis | ||||||||
| Synchronous | 79 (38.2) | 415.8 | 35.0 | 0.469 | 77 (39.9) | 2.68 | 0.23 | 0.150 |
| Metachronous | 128 (61.8) | 437.9 | 25.2 | 116 (60.1) | 3.07 | 0.22 | ||
| Number of metastases | ||||||||
| Single | 86 (41.5) | 424.0 | 37.7 | 0.050 | 78 (40.4) | 2.64 | 0.21 | 0.448 |
| Multiple | 121 (58.5) | 433.4 | 22.7 | 115 (59.6) | 3.09 | 0.24 | ||
| Diameter of largest metastasis | ||||||||
| ≤5 cm | 168 (81.2) | 402.1 | 20.9 | 0.027 | 157 (81.3) | 2.72 | 0.16 | 0.180 |
| >5 cm | 39 (18.8) | 547.7 | 58.2 | 36 (18.7) | 3.74 | 0.54 | ||
| Disease-free interval | ||||||||
| ≥12months | 63 (30.4) | 448.4 | 39.2 | 0.920 | 58 (30.1) | 3.26 | 0.28 | 0.020 |
| <12months | 144 (69.6) | 421.2 | 24.0 | 135 (69.9) | 2.76 | 0.20 | ||
| CEA level | ||||||||
| ≤200 ng/mL | 198 (96.6) | 433.0 | 21.3 | 0.933 | 187 (97.4) | 2.84 | 0.16 | 0.014 |
| >200 ng/mL | 7 (3.4) | 385.3 | 57.9 | 5 (2.6) | 5.90 | 1.35 | ||
| Clinical Risk Score* | ||||||||
| Low risk | 122 (60.7) | 431.4 | 30.1 | 0.276 | 115 (61.2) | 2.62 | 0.17 | 0.203 |
| High risk | 79 (39.3) | 417.3 | 24.6 | 73 (38.8) | 3.38 | 0.33 | ||
| Margin liver resection | ||||||||
| Negative | 190 (91.8) | 418.7 | 19.1 | 0.645 | 177 (91.7) | 2.81 | 0.16 | 0.226 |
| Positive | 17 (8.2) | 550.4 | 129.4 | 16 (8.3) | 4.03 | 0.90 | ||
| Tertiary lymphoid structure | ||||||||
| No | 184 (88.9) | 426.8 | 21.8 | 0.481 | 174 (90.6) | 2.91 | 0.17 | 0.972 |
| Yes | 23 (11.1) | 451.2 | 60.2 | 18 (9.4) | 3.03 | 0.53 | ||
| Primary tumor | ||||||||
| Left colon | 153 (74.3) | 418.1 | 21.2 | 0.865 | 137 (71.4) | 3.06 | 0.20 | 0.074 |
| Right colon | 53 (25.7) | 446.0 | 49.1 | 55 (28.6) | 2.54 | 0.30 | ||
| pT category | ||||||||
| pT1-pT3 | 161 (83.9) | 422.8 | 24.2 | 0.069 | 150 (83.8) | 2.83 | 0.18 | 0.573 |
| pT4 | 31 (16.1) | 452.9 | 36.8 | 29 (16.2) | 3.19 | 0.50 | ||
| pN category | ||||||||
| pN0 | 73 (36) | 436.1 | 37.2 | 0.887 | 69 (36.5) | 2.82 | 0.28 | 0.639 |
| pN+ | 130 (64) | 420.3 | 24.6 | 120 (63.5) | 2.89 | 0.20 | ||
| Preop chemotherapy | ||||||||
| No | 45 (21.7) | 426.1 | 49.0 | 0.289 | 41 (21.2) | 2.62 | 0.27 | 0.684 |
| Yes | 162 (78.3) | 430.4 | 22.5 | 152 (78.8) | 2.99 | 0.19 | ||
| 5FU, leucovorin, oxaliplatin-based | ||||||||
| No | 20 (12.3) | 441.5 | 67.9 | 0.943 | 19 (12.5) | 3.17 | 0.47 | 0.491 |
| Yes | 142 (87.7) | 428.9 | 23.9 | 133 (87.5) | 2.96 | 0.21 | ||
| Bevacizumab | ||||||||
| No | 35 (21.6) | 394.3 | 37.7 | 0.441 | 34 (22.4) | 2.87 | 0.41 | 0.652 |
| Yes | 127 (78.4) | 440.4 | 26.7 | 118 (77.6) | 3.02 | 0.22 | ||
| Tumor regression grade | ||||||||
| 1-2 | 27 (17) | 351.1 | 36.1 | 0.032 | 29 (19.6) | 2.34 | 0.32 | 0.077 |
| 3-4-5 | 132 (83) | 449.1 | 26.3 | 119 (80.4) | 3.21 | 0.23 | ||
| Extrahepatic recurrence | ||||||||
| No | 63 (42.9) | 420.9 | 39.0 | 0.344 | 59 (43.7) | 2.58 | 0.23 | 0.462 |
| Yes | 84 (57.1) | 473.0 | 35.2 | 76 (56.3) | 3.05 | 0.28 |
Abbreviations: tCD73, tumoral CD73 expression in CRLM; sCD73, soluble CD73 measured in serum; CEA, Carcinoembryoinic Antigen; T, Tumor; N, Node; SEM, Standard error of the mean. *Clinical Risk Score calculated giving one point for each of the following clinicopathologic characteristics, and where low risk is defined as 0 to 2 points, high risk as 3 to 5 points: node-positive (N+) primary cancer, disease-free interval (time between resection of primary and liver recurrence) <12 months, more than 1 liver metastasis, largest liver metastasis >5 cm, and prehepatectomy serum carcinoembryonic antigen (CEA) level >200 ng/ml.